Cleared Traditional

K874464 - SPERMICIDAL CONDOM

K874464 is the FDA 510(k) clearance for SPERMICIDAL CONDOM by Royal American Industries, Inc.. It is a Class 2 Obstetrics & Gynecology device (product code HIS) cleared through the Traditional 510(k) pathway after a 25-day FDA review.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 1987
Decision
25d
Days
Class 2
Risk

K874464 is an FDA 510(k) clearance for the SPERMICIDAL CONDOM. Classified as Condom (product code HIS), Class II - Special Controls.

Submitted by Royal American Industries, Inc. (Boca Raton, US). The FDA issued a Cleared decision on November 20, 1987 after a review of 25 days - a notably fast clearance cycle.

This device falls under the Obstetrics & Gynecology FDA review panel, regulated under 21 CFR 884.5300 - the FDA obstetrics and gynecology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Royal American Industries, Inc. devices

Submission Details

510(k) Number K874464 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 26, 1987
Decision Date November 20, 1987
Days to Decision 25 days
Submission Type Traditional
Review Panel Obstetrics & Gynecology (OB)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
135d faster than avg
Panel avg: 160d · This submission: 25d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code HIS Condom
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 884.5300
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Obstetrics & Gynecology devices follow this clearance model.